亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯系方式|購物車
企業會員第1年

浙江臺州市保隆化工有限公司  

抗腫瘤產品,醋酸格拉替雷

搜索
新聞中心
  • 暫無新聞
產品分類
  • 暫無分類
聯系方式
  • 聯系人:董女士
  • 電話:86-0576-88702852
  • 郵件:eric@bolonpharm.com
站內搜索
 
榮譽資質
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應產品 > 羅氟司特162401-32-3
羅氟司特162401-32-3
單價 面議對比
詢價 暫無
發貨 浙江付款后3天內
過期 長期有效
更新 2014-03-12 14:28
 
詳細信息

中文名稱:

羅氟司特

中文同義詞:

羅氟司特/ ROFLUMILAST/3-(環丙甲氧基)-N-(3,5-二氯-4-吡啶基)-4-(二氟甲氧基)苯甲酰胺;3-(環丙基甲氧基)-N-(3,5-二氯吡啶-4-)-4-(二氟甲氧基)苯甲酰胺;羅氟司特;3-(環丙甲氧基)-N-(3,5-二氯-4-吡啶基)-4-(二氟甲氧基)苯甲酰胺;ROFLUMILAST INN;達菲寧

英文名稱:

Roflumilast

英文同義詞:

ROFLUMILAST;3-(Cyclopropylmethoxy)-N-(3,5-dichloro-4-pyridinyl)-4-(difluoromethoxy)benzamide;B 9302-107;BY 217;BYK 20869;Daxas;Roflumilast / 3-(cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide;3-(Cyclopropylmethoxy)-N-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide

CAS:

162401-32-3

分子式:

C17H14Cl2F2N2O3

分子量:

403.21

EINECS:

 

Mol文件:

162401-32-3.mol

©2025 浙江臺州市保隆化工有限公司 版權所有   技術支持:化工網   訪問量:4599  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |